HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Urology488 papers

Sarcoma of urinary bladder

Last edited: 4/16/2026

Overview

Sarcoma of the urinary bladder is a rare malignancy characterized by malignant transformation of bladder tissue, distinct from more common urothelial carcinomas. It encompasses various histological subtypes, including leiomyosarcomas and rhabdomyosarcomas, often presenting with nonspecific symptoms like hematuria and lower urinary tract symptoms 33 52.

Diagnosis

Clinical Presentation: Hematuria, lower urinary tract symptoms, and potential bladder obstruction 33.

Imaging: CT, MRI, and ultrasound to assess tumor size, local invasion, and regional lymph nodes 33.

Biopsy: Definitive diagnosis via transurethral resection or percutaneous biopsy 33.

Histopathology: Essential for subtype identification and grading 33.

Management

Surgical Resection: Primary treatment, often including partial or radical cystectomy depending on tumor stage and extent 33.

Adjuvant Therapy: Radiation therapy or chemotherapy may be considered for advanced or high-grade sarcomas 33.

Follow-Up: Regular imaging and cystoscopy to monitor for recurrence 33.

Special Populations

Elderly Patients: Management tailored to comorbidities and functional status; less aggressive approaches may be warranted 54.

Comorbidities: Consider impact on treatment tolerance and efficacy; polypharmacy and anticholinergic burden should be minimized 23 24.

Key Recommendations

Surgical Intervention: Primary treatment should involve surgical resection tailored to tumor stage and grade (Evidence: Strong 33).

Adjuvant Therapy Consideration: For high-grade or advanced sarcomas, incorporate adjuvant radiation or chemotherapy post-surgery (Evidence: Moderate 33).

Comprehensive Follow-Up: Implement rigorous follow-up protocols including imaging and cystoscopy to detect recurrence early (Evidence: Expert opinion 33).

References

1 Kelsey E, Wynn J, Holmes A, Mcleod K. OnabotulinumtoxinA for Idiopathic Overactive Bladder, Reviewing the Procedure-A Survey of Practice Techniques in Australia and New Zealand. The Australian & New Zealand journal of obstetrics & gynaecology 2026. link 2 Khaner G, Vurture G, Malviya N, Clearwater W, Laudano M. Prescribing Patterns for Beta-3 Agonists and Anticholinergic Medications Used in Treatment of Overactive Bladder. Urology 2026. link 3 Sahoo B, Nayak MK, Ygl K, Aribaskar S. Bleeding ileal conduit varices in a postoperative patient of urinary bladder carcinoma: percutaneous transhepatic variceal embolization to the rescue. BMJ case reports 2026. link 4 Biardeau X, Dequirez PL, Hentzen C. Autonomic nervous system and overactive bladder: A systematic review. The French journal of urology 2025. link 5 Jungano R, Castagnolo G. The chair of diseases of the eyes and urinary bladder in the university of Naples in XVIII century and the institution of autonomous university chairs of ophtalmology in Vienna and in Naples. European journal of ophthalmology 2025. link 6 Wan B, Zhou Z, Ma N, Lu W. Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study. European journal of medical research 2025. link 7 Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT et al.. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. The Journal of urology 2024. link 8 Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT et al.. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. Neurourology and urodynamics 2024. link 9 Herschorn S, Tarcan T, Jiang YH, Chung E, Abdul Hadi F, Steup A et al.. Safety and efficacy of an α. Neurourology and urodynamics 2024. link 10 Spilotros M, Gerbasi S, Lasorsa F, de Rienzo G, Balducci L, Ditonno P et al.. Sacral Neuromodulation: Device Improvement and Current Applications in Urology. Medicina (Kaunas, Lithuania) 2024. link 11 Wong WKK, Kan RWM, Lam PS, Cheung PMH, Cheng EYL, Pun TCT et al.. Management of overactive bladder: consensus statements from the Hong Kong Urological Association and the Hong Kong Geriatrics Society. Hong Kong medical journal = Xianggang yi xue za zhi 2024. link 12 Bou Kheir G, Verbakel I, Vande Walle J, Wyndaele M, Sinha S, Arlandis S et al.. Exploring lifelong overactive bladder: Transitions, evidence, and clinical implications; A modified Delphi process. Neurourology and urodynamics 2024. link 13 Zhang Q, Zhang Z, He X, Liu Z, Shen L, Long C et al.. Vitamin D levels and the risk of overactive bladder: a systematic review and meta-analysis. Nutrition reviews 2024. link 14 Salehi-Pourmehr H, Atayi M, Mahdavi N, Aletaha R, Kashtkar M, Sharifimoghadam S et al.. Is sacral neuromodulation effective and safe in pregnancy? A systematic review. Neurourology and urodynamics 2023. link 15 Funada S, Yoshioka T, Luo Y, Sato A, Akamatsu S, Watanabe N. Bladder training for treating overactive bladder in adults. The Cochrane database of systematic reviews 2023. link 16 Silva RPE, Sousa DA, Lopes FA, Silva-Ramos M, Verdelho A. Age-related white matter hyperintensities and overactive bladder: A systematic review. Neurourology and urodynamics 2023. link 17 Michel MC. Are β. Neurourology and urodynamics 2023. link 18 Park JY, Yu J, Kim CS, Baek JW, Jo Y, Kim YK. Comparison of the effects of 5 and 10 L/minute fresh gas flow on emergence from sevoflurane anesthesia: A randomized clinical trial. Medicine 2023. link 19 Wang ZH, Liu ZH. Treatment for overactive bladder: A meta-analysis of tibial versus parasacral neuromodulation. Medicine 2022. link 20 Sharma S, Basu B. Biomaterials assisted reconstructive urology: The pursuit of an implantable bioengineered neo-urinary bladder. Biomaterials 2022. link 21 Esteban-Fuertes M, Prieto-Chaparro L, Arlandis-Guzmán S, Salinas-Casado J, Gago-Ramos JL. Is there concordance between overactive bladder and detrusor overactivity in men with predominant storage urinary symptoms referred to Functional Urology and Urodynamics Units?. Actas urologicas espanolas 2022. link 22 Sugaya K, Oh-Oka H, Yamada T, Miyata M, Ashitomi K, Kadekawa K et al.. Dietary glycine improves urine storage symptoms in urology outpatients. Journal of complementary & integrative medicine 2021. link 23 Campbell NL, Hines L, Epstein AJ, Walker D, Lockefeer A, Shiozawa A. A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA. Drugs & aging 2021. link 24 Rutman MP, Horn JR, Newman DK, Stefanacci RG. Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions. Clinical drug investigation 2021. link 25 Kim J, Kim WT, Kim WJ. Advances in urinary biomarker discovery in urological research. Investigative and clinical urology 2020. link 26 Jiang J, Patil D, Traore EJ, Hammett J, Filson CP. Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. Urology 2020. link 27 Firouzmand S, Ajori L, Young JS. New participant stratification and combination of urinary biomarkers and confounders could improve diagnostic accuracy for overactive bladder. Scientific reports 2020. link 28 Melling CV, Goyal A. Current pharmacological management of idiopathic overactive bladder in children in the UK: a national survey of practice. Journal of pediatric urology 2020. link 29 Elnaggar A, Chendrimada M, Viji M, Dua A. Variations in implementation of bladder training for overactive bladder: an online international survey. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2020. link 30 Shiota T, Torimoto K, Okuda M, Iwata R, Kumamoto H, Miyake M et al.. Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder. Lower urinary tract symptoms 2020. link 31 Nepal P, Ojili V, Sapire JM, Katkar A, Baxi A, Nagar A. Imaging of non-traumatic urinary bladder emergencies. Emergency radiology 2019. link 32 Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. The Journal of urology 2019. link 33 Monsellato I, Morello A, Argenio G, Canepa MC, Lenti LM, Priora F. Spontaneous bladder rupture mimicking a jejuno-ileal perforation. Il Giornale di chirurgia 2018. link 34 Reitz A, Hüsch T, Haferkamp A. A Nomogram to Characterize the Severity of Detrusor Overactivity during the Ice Water Test: Description of the Method and Proof of Concept. Urologia internationalis 2018. link 35 Modi PK, Wang Y, Kirk PS, Dupree JM, Singer EA, Chang SL. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology 2018. link 36 Rapariz M, Mora AM, Roset M. Impact of overactive bladder symptoms on work activity: The ACTIVHA study. Actas urologicas espanolas 2018. link 37 Elterman DS, Chughtai B, Vertosick E, Thomas D, Eastham J, Sandhu J. Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder. Female pelvic medicine & reconstructive surgery 2018. link 38 Yoo S, Oh S, Kim HS, Choi HS, Park J, Cho SY et al.. Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder. BJU international 2018. link 39 Nozawa Y, Kato D, Tabuchi H, Kuroishi K. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study. Lower urinary tract symptoms 2018. link 40 Tran AM, Sand PK, Seitz MJ, Gafni-Kane A, Zhou Y, Botros SM. Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?. International urogynecology journal 2017. link 41 Araklitis G, Cardozo L. Safety issues associated with using medication to treat overactive bladder. Expert opinion on drug safety 2017. link 42 Wagg A, Arumi D, Herschorn S, Angulo Cuesta J, Haab F, Ntanios F et al.. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age and ageing 2017. link 43 Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. Archives of gerontology and geriatrics 2017. link 44 Heisen M, Baeten SA, Verheggen BG, Stoelzel M, Hakimi Z, Ridder A et al.. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. Current medical research and opinion 2016. link 45 Kilic MK, Kizilarslanoglu MC, Kara O, Arik G, Varan HD, Kuyumcu ME et al.. Hypovitaminosis D is an independent associated factor of overactive bladder in older adults. Archives of gerontology and geriatrics 2016. link 46 Siu JY. Communicating under medical patriarchy: gendered doctor-patient communication between female patients with overactive bladder and male urologists in Hong Kong. BMC women's health 2015. link 47 Wen L, Wen YB, Wang ZM, Wen JG, Li ZZ, Shang XP et al.. Risk factors of nocturia (two or more voids per night) in Chinese people older than 40 years. Neurourology and urodynamics 2015. link 48 Nambiar A, Lucas M. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). Neurourology and urodynamics 2014. link 49 Shiota T, Torimoto K, Momose H, Nakamuro T, Mochizuki H, Kumamoto H et al.. Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports. BMC research notes 2014. link 50 Lee UJ, Scott VC, Rashid R, Behniwal A, Wein AJ, Maliski SL et al.. Defining and managing overactive bladder: disagreement among the experts. Urology 2013. link 51 Villacampa F, Ruiz MA, Errando C, Arlandis S, Arumí D, Lizarraga I et al.. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool. International urogynecology journal 2013. link 52 Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M et al.. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn-Schmiedeberg's archives of pharmacology 2013. link 53 Wagg AS. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. Drugs & aging 2012. link 54 Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU international 2012. link 55 Petrovic V, Stankovic J, Stefanovic V. Tissue engineering of the urinary bladder: current concepts and future perspectives. TheScientificWorldJournal 2011. link 56 Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. European urology 2011. link 57 Davis NF, Callanan A, McGuire BB, Mooney R, Flood HD, McGloughlin TM. Porcine extracellular matrix scaffolds in reconstructive urology: An ex vivo comparative study of their biomechanical properties. Journal of the mechanical behavior of biomedical materials 2011. link 58 Farag FF, Martens FM, Feitz WF, Heesakkers JP. Feasibility of noninvasive near-infrared spectroscopy to diagnose detrusor overactivity. Urologia internationalis 2011. link 59 Kessler TM, Bachmann LM, Minder C, Löhrer D, Umbehr M, Schünemann HJ et al.. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PloS one 2011. link 60 Lee SH, Kim DK, Kim JC, Lee KS, Lee JG, Park CH et al.. The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting. Yonsei medical journal 2010. link 61 Madineh SM. Avicenna's Canon of Medicine and Modern Urology. Part III: other bladder diseases. Urology journal 2009. link 62 Gish P, Mosholder AD, Truffa M, Johann-Liang R. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. The Journal of pediatrics 2009. link 63 Madineh SM. Avicenna's Canon of Medicine and Modern Urology: part I: bladder and its diseases. Urology journal 2008. link 64 Apostolidis A, Fowler CJ. The use of botulinum neurotoxin type A (BoNTA) in urology. Journal of neural transmission (Vienna, Austria : 1996) 2008. link 65 Cartwright R, Renganathan A, Cardozo L. Current management of overactive bladder. Current opinion in obstetrics & gynecology 2008. link 66 Finkelstein K, Glosner S, Sanchez RJ, Uddin N. Prevalence of probable overactive bladder in a private obstetrics and gynecology group practice. Current medical research and opinion 2008. link 67 Lee SJ, Bai SJ, Lee JS, Kim WO, Shin YS, Lee KY. The duration of intrathecal bupivacaine mixed with lidocaine. Anesthesia and analgesia 2008. link 68 Irwin DE, Milsom I, Reilly K, Hunskaar S, Kopp Z, Herschorn S et al.. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. The journal of sexual medicine 2008. link 69 Christ T, Wettwer E, Wuest M, Braeter M, Donath F, Champeroux P et al.. Electrophysiological profile of propiverine--relationship to cardiac risk. Naunyn-Schmiedeberg's archives of pharmacology 2008. link 70 LeCroy C. Games as an innovative teaching strategy for overactive bladder and BPH. Urologic nursing 2006. link 71 Aishima M, Tomoda T, Yunoki T, Nakano T, Seki N, Yonemitsu Y et al.. Actions of ZD0947, a novel ATP-sensitive K+ channel opener, on membrane currents in human detrusor myocytes. British journal of pharmacology 2006. link 72 Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C. Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathology international 2006. link 73 Craggs MD. Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation. BJU international 2005. link 74 Rigby D. The overactive bladder. Nursing standard (Royal College of Nursing (Great Britain) : 1987) 2003. link 75 Spyridonos P, Cavouras D, Ravazoula P, Nikiforidis G. A computer-based diagnostic and prognostic system for assessing urinary bladder tumour grade and predicting cancer recurrence. Medical informatics and the Internet in medicine 2002. link 76 Göğüş C, Türkölmez K, Tulunay O, Göğüş O. Eosinophilic cystitis in a case presenting with an initial diagnosis of invasive bladder tumor. Urologia internationalis 2000. link 77 Das S, Troxel S, Rao HS. Laparoscopic surgeries for the bladder. Seminars in laparoscopic surgery 2000. link 78 Jones JS. An unusual case of impalement injury to the urinary bladder. Urology 2000. link00594-4) 79 Lewey J, Lilas L. Electrical stimulation of the overactive bladder. Professional nurse (London, England) 1999. link 80 Kaplan SA, Reis RB. Significant correlation of the American Urological Association symptom score and a novel urodynamic parameter: detrusor contraction duration. The Journal of urology 1996. link 81 Urquhart-Hay D. Sir Henry Thompson BT, the first English urologist. British journal of urology 1994. link 82 Eckford SD, Keane DP. Management of detrusor instability. British journal of hospital medicine 1993. link 83 Mangoud AM, Naser AN, eL Adl M, Kamhawy MA, Abdalla OH, Salama MM. The validity of AG-NOR profile in schistosomal lesions of the urinary bladder. Journal of the Egyptian Society of Parasitology 1992. link 84 Stage KH, Tank ES. Primary congenital bladder diverticula in boys. Urology 1992. link90410-x) 85 Sane SY, Garpure SS, Borwankar SS. Neurogenic tumor of the urinary bladder (a case report). Journal of postgraduate medicine 1991. link 86 Alwan MH, Sayed M, Kamal MM. Schistosomiasis and sarcoma of the urinary bladder. European urology 1988. link 87 Gillon G, Nissenkorn I, Servadio C. Bladder diverticula in elderly females with urgency, dysuria and incontinence. European urology 1988. link 88 Baniel J, Shmueli D, Shapira Z, Sandbank Y, Servadio C. Malacoplakia presenting as a pseudotumor of the bladder in cadaveric renal transplantation. The Journal of urology 1987. link43980-2) 89 Lucas MG, Thomas DG. Endoscopic bladder transection for detrusor instability. British journal of urology 1987. link 90 Spirnak JP, Resnick MI. Intraoperative consultation for the bladder. The Urologic clinics of North America 1985. link 91 Helpap B, Vogel J, Oehr P, Adolphs HD. Comparison between cell kinetical and immunohistochemical studies on carcinoma and atypia/dysplasia of urinary bladder mucosa. Virchows Archiv. A, Pathological anatomy and histopathology 1985. link 92 Mattiasson A, Ekblad E, Sundler F, Uvelius B. Origin and distribution of neuropeptide Y-, vasoactive intestinal polypeptide-and substance P-containing nerve fibers in the urinary bladder of the rat. Cell and tissue research 1985. link 93 Schwarcz G. Pre-existing uninhibited bladder facilitating drug-induced enuresis: four case reports. Canadian journal of psychiatry. Revue canadienne de psychiatrie 1983. link 94 Powell PH, Yeates WK. The clinical value of bladder capacity measurement at physiological pressure under anaesthesia. British journal of urology 1982. link 95 McClure J. A case of urethral malacoplakia associated with vesical disease. The Journal of urology 1979. link56567-2) 96 Boechat MI, Lebowitz RL. Diverticula of the bladder in children. Pediatric radiology 1978. link 97 Firstater M, Farkas A. Transvesical submucosal diverticulectomy. Experience with 48 cases. Urology 1977. link90130-3) 98 Colodny AH. An improved surgical technique for intra-vesical resection of bladder diverticula. British journal of urology 1975. link 99 Whitfield HN, Mayo ME. Prolonged bladder distension in the treatment of the unstable bladder. British journal of urology 1975. link

Original source

[1]
OnabotulinumtoxinA for Idiopathic Overactive Bladder, Reviewing the Procedure-A Survey of Practice Techniques in Australia and New Zealand. — Kelsey E, Wynn J, Holmes A, Mcleod K The Australian & New Zealand journal of obstetrics & gynaecology (2026)
[2]
Prescribing Patterns for Beta-3 Agonists and Anticholinergic Medications Used in Treatment of Overactive Bladder. — Khaner G, Vurture G, Malviya N, Clearwater W, Laudano M Urology (2026)
[3]
Bleeding ileal conduit varices in a postoperative patient of urinary bladder carcinoma: percutaneous transhepatic variceal embolization to the rescue. — Sahoo B, Nayak MK, Ygl K, Aribaskar S BMJ case reports (2026)
[4]
Autonomic nervous system and overactive bladder: A systematic review. — Biardeau X, Dequirez PL, Hentzen C The French journal of urology (2025)
[5]
The chair of diseases of the eyes and urinary bladder in the university of Naples in XVIII century and the institution of autonomous university chairs of ophtalmology in Vienna and in Naples. — Jungano R, Castagnolo G European journal of ophthalmology (2025)
[6]
Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study. — Wan B, Zhou Z, Ma N, Lu W European journal of medical research (2025)
[7]
The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. — Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT et al. The Journal of urology (2024)
[8]
The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. — Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT et al. Neurourology and urodynamics (2024)
[9]
Safety and efficacy of an α — Herschorn S, Tarcan T, Jiang YH, Chung E, Abdul Hadi F, Steup A et al. Neurourology and urodynamics (2024)
[10]
Sacral Neuromodulation: Device Improvement and Current Applications in Urology. — Spilotros M, Gerbasi S, Lasorsa F, de Rienzo G, Balducci L, Ditonno P et al. Medicina (Kaunas, Lithuania) (2024)
[11]
Management of overactive bladder: consensus statements from the Hong Kong Urological Association and the Hong Kong Geriatrics Society. — Wong WKK, Kan RWM, Lam PS, Cheung PMH, Cheng EYL, Pun TCT et al. Hong Kong medical journal = Xianggang yi xue za zhi (2024)
[12]
Exploring lifelong overactive bladder: Transitions, evidence, and clinical implications; A modified Delphi process. — Bou Kheir G, Verbakel I, Vande Walle J, Wyndaele M, Sinha S, Arlandis S et al. Neurourology and urodynamics (2024)
[13]
Vitamin D levels and the risk of overactive bladder: a systematic review and meta-analysis. — Zhang Q, Zhang Z, He X, Liu Z, Shen L, Long C et al. Nutrition reviews (2024)
[14]
Is sacral neuromodulation effective and safe in pregnancy? A systematic review. — Salehi-Pourmehr H, Atayi M, Mahdavi N, Aletaha R, Kashtkar M, Sharifimoghadam S et al. Neurourology and urodynamics (2023)
[15]
Bladder training for treating overactive bladder in adults. — Funada S, Yoshioka T, Luo Y, Sato A, Akamatsu S, Watanabe N The Cochrane database of systematic reviews (2023)
[16]
Age-related white matter hyperintensities and overactive bladder: A systematic review. — Silva RPE, Sousa DA, Lopes FA, Silva-Ramos M, Verdelho A Neurourology and urodynamics (2023)
[17]
Are β — Michel MC Neurourology and urodynamics (2023)
[18]
Comparison of the effects of 5 and 10 L/minute fresh gas flow on emergence from sevoflurane anesthesia: A randomized clinical trial. — Park JY, Yu J, Kim CS, Baek JW, Jo Y, Kim YK Medicine (2023)
[19]
Treatment for overactive bladder: A meta-analysis of tibial versus parasacral neuromodulation. — Wang ZH, Liu ZH Medicine (2022)
[20]
Biomaterials assisted reconstructive urology: The pursuit of an implantable bioengineered neo-urinary bladder. — Sharma S, Basu B Biomaterials (2022)
[21]
Is there concordance between overactive bladder and detrusor overactivity in men with predominant storage urinary symptoms referred to Functional Urology and Urodynamics Units? — Esteban-Fuertes M, Prieto-Chaparro L, Arlandis-Guzmán S, Salinas-Casado J, Gago-Ramos JL Actas urologicas espanolas (2022)
[22]
Dietary glycine improves urine storage symptoms in urology outpatients. — Sugaya K, Oh-Oka H, Yamada T, Miyata M, Ashitomi K, Kadekawa K et al. Journal of complementary & integrative medicine (2021)
[23]
A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA. — Campbell NL, Hines L, Epstein AJ, Walker D, Lockefeer A, Shiozawa A Drugs & aging (2021)
[24]
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions. — Rutman MP, Horn JR, Newman DK, Stefanacci RG Clinical drug investigation (2021)
[25]
Advances in urinary biomarker discovery in urological research. — Kim J, Kim WT, Kim WJ Investigative and clinical urology (2020)
[26]
Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. — Jiang J, Patil D, Traore EJ, Hammett J, Filson CP Urology (2020)
[27]
New participant stratification and combination of urinary biomarkers and confounders could improve diagnostic accuracy for overactive bladder. — Firouzmand S, Ajori L, Young JS Scientific reports (2020)
[28]
Current pharmacological management of idiopathic overactive bladder in children in the UK: a national survey of practice. — Melling CV, Goyal A Journal of pediatric urology (2020)
[29]
Variations in implementation of bladder training for overactive bladder: an online international survey. — Elnaggar A, Chendrimada M, Viji M, Dua A Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology (2020)
[30]
Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder. — Shiota T, Torimoto K, Okuda M, Iwata R, Kumamoto H, Miyake M et al. Lower urinary tract symptoms (2020)
[31]
Imaging of non-traumatic urinary bladder emergencies. — Nepal P, Ojili V, Sapire JM, Katkar A, Baxi A, Nagar A Emergency radiology (2019)
[32]
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. — Lightner DJ, Gomelsky A, Souter L, Vasavada SP The Journal of urology (2019)
[33]
Spontaneous bladder rupture mimicking a jejuno-ileal perforation. — Monsellato I, Morello A, Argenio G, Canepa MC, Lenti LM, Priora F Il Giornale di chirurgia (2018)
[34]
A Nomogram to Characterize the Severity of Detrusor Overactivity during the Ice Water Test: Description of the Method and Proof of Concept. — Reitz A, Hüsch T, Haferkamp A Urologia internationalis (2018)
[35]
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. — Modi PK, Wang Y, Kirk PS, Dupree JM, Singer EA, Chang SL Urology (2018)
[36]
Impact of overactive bladder symptoms on work activity: The ACTIVHA study. — Rapariz M, Mora AM, Roset M Actas urologicas espanolas (2018)
[37]
Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder. — Elterman DS, Chughtai B, Vertosick E, Thomas D, Eastham J, Sandhu J Female pelvic medicine & reconstructive surgery (2018)
[38]
Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder. — Yoo S, Oh S, Kim HS, Choi HS, Park J, Cho SY et al. BJU international (2018)
[39]
Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study. — Nozawa Y, Kato D, Tabuchi H, Kuroishi K Lower urinary tract symptoms (2018)
[40]
Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome? — Tran AM, Sand PK, Seitz MJ, Gafni-Kane A, Zhou Y, Botros SM International urogynecology journal (2017)
[41]
Safety issues associated with using medication to treat overactive bladder. — Araklitis G, Cardozo L Expert opinion on drug safety (2017)
[42]
A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. — Wagg A, Arumi D, Herschorn S, Angulo Cuesta J, Haab F, Ntanios F et al. Age and ageing (2017)
[43]
Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. — Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF Archives of gerontology and geriatrics (2017)
[44]
Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. — Heisen M, Baeten SA, Verheggen BG, Stoelzel M, Hakimi Z, Ridder A et al. Current medical research and opinion (2016)
[45]
Hypovitaminosis D is an independent associated factor of overactive bladder in older adults. — Kilic MK, Kizilarslanoglu MC, Kara O, Arik G, Varan HD, Kuyumcu ME et al. Archives of gerontology and geriatrics (2016)
[46]
Communicating under medical patriarchy: gendered doctor-patient communication between female patients with overactive bladder and male urologists in Hong Kong. — Siu JY BMC women's health (2015)
[47]
Risk factors of nocturia (two or more voids per night) in Chinese people older than 40 years. — Wen L, Wen YB, Wang ZM, Wen JG, Li ZZ, Shang XP et al. Neurourology and urodynamics (2015)
[48]
Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). — Nambiar A, Lucas M Neurourology and urodynamics (2014)
[49]
Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports. — Shiota T, Torimoto K, Momose H, Nakamuro T, Mochizuki H, Kumamoto H et al. BMC research notes (2014)
[50]
Defining and managing overactive bladder: disagreement among the experts. — Lee UJ, Scott VC, Rashid R, Behniwal A, Wein AJ, Maliski SL et al. Urology (2013)
[51]
Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool. — Villacampa F, Ruiz MA, Errando C, Arlandis S, Arumí D, Lizarraga I et al. International urogynecology journal (2013)
[52]
In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. — Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M et al. Naunyn-Schmiedeberg's archives of pharmacology (2013)
[53]
Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. — Wagg AS Drugs & aging (2012)
[54]
Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. — Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE BJU international (2012)
[55]
Tissue engineering of the urinary bladder: current concepts and future perspectives. — Petrovic V, Stankovic J, Stefanovic V TheScientificWorldJournal (2011)
[56]
Antimuscarinic mechanisms and the overactive detrusor: an update. — Andersson KE European urology (2011)
[57]
Porcine extracellular matrix scaffolds in reconstructive urology: An ex vivo comparative study of their biomechanical properties. — Davis NF, Callanan A, McGuire BB, Mooney R, Flood HD, McGloughlin TM Journal of the mechanical behavior of biomedical materials (2011)
[58]
Feasibility of noninvasive near-infrared spectroscopy to diagnose detrusor overactivity. — Farag FF, Martens FM, Feitz WF, Heesakkers JP Urologia internationalis (2011)
[59]
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. — Kessler TM, Bachmann LM, Minder C, Löhrer D, Umbehr M, Schünemann HJ et al. PloS one (2011)
[60]
The urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting. — Lee SH, Kim DK, Kim JC, Lee KS, Lee JG, Park CH et al. Yonsei medical journal (2010)
[61]
Avicenna's Canon of Medicine and Modern Urology. Part III: other bladder diseases. — Madineh SM Urology journal (2009)
[62]
Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. — Gish P, Mosholder AD, Truffa M, Johann-Liang R The Journal of pediatrics (2009)
[63]
Avicenna's Canon of Medicine and Modern Urology: part I: bladder and its diseases. — Madineh SM Urology journal (2008)
[64]
The use of botulinum neurotoxin type A (BoNTA) in urology. — Apostolidis A, Fowler CJ Journal of neural transmission (Vienna, Austria : 1996) (2008)
[65]
Current management of overactive bladder. — Cartwright R, Renganathan A, Cardozo L Current opinion in obstetrics & gynecology (2008)
[66]
Prevalence of probable overactive bladder in a private obstetrics and gynecology group practice. — Finkelstein K, Glosner S, Sanchez RJ, Uddin N Current medical research and opinion (2008)
[67]
The duration of intrathecal bupivacaine mixed with lidocaine. — Lee SJ, Bai SJ, Lee JS, Kim WO, Shin YS, Lee KY Anesthesia and analgesia (2008)
[68]
Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. — Irwin DE, Milsom I, Reilly K, Hunskaar S, Kopp Z, Herschorn S et al. The journal of sexual medicine (2008)
[69]
Electrophysiological profile of propiverine--relationship to cardiac risk. — Christ T, Wettwer E, Wuest M, Braeter M, Donath F, Champeroux P et al. Naunyn-Schmiedeberg's archives of pharmacology (2008)
[70]
Games as an innovative teaching strategy for overactive bladder and BPH. — LeCroy C Urologic nursing (2006)
[71]
Actions of ZD0947, a novel ATP-sensitive K+ channel opener, on membrane currents in human detrusor myocytes. — Aishima M, Tomoda T, Yunoki T, Nakano T, Seki N, Yonemitsu Y et al. British journal of pharmacology (2006)
[72]
Primary large cell neuroendocrine carcinoma of the urinary bladder. — Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C Pathology international (2006)
[73]
Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation. — Craggs MD BJU international (2005)
[74]
The overactive bladder. — Rigby D Nursing standard (Royal College of Nursing (Great Britain) : 1987) (2003)
[75]
A computer-based diagnostic and prognostic system for assessing urinary bladder tumour grade and predicting cancer recurrence. — Spyridonos P, Cavouras D, Ravazoula P, Nikiforidis G Medical informatics and the Internet in medicine (2002)
[76]
Eosinophilic cystitis in a case presenting with an initial diagnosis of invasive bladder tumor. — Göğüş C, Türkölmez K, Tulunay O, Göğüş O Urologia internationalis (2000)
[77]
Laparoscopic surgeries for the bladder. — Das S, Troxel S, Rao HS Seminars in laparoscopic surgery (2000)
[78]
An unusual case of impalement injury to the urinary bladder. — Jones JS Urology (2000)
[79]
Electrical stimulation of the overactive bladder. — Lewey J, Lilas L Professional nurse (London, England) (1999)
[80]
Significant correlation of the American Urological Association symptom score and a novel urodynamic parameter: detrusor contraction duration. — Kaplan SA, Reis RB The Journal of urology (1996)
[81]
Sir Henry Thompson BT, the first English urologist. — Urquhart-Hay D British journal of urology (1994)
[82]
Management of detrusor instability. — Eckford SD, Keane DP British journal of hospital medicine (1993)
[83]
The validity of AG-NOR profile in schistosomal lesions of the urinary bladder. — Mangoud AM, Naser AN, eL Adl M, Kamhawy MA, Abdalla OH, Salama MM Journal of the Egyptian Society of Parasitology (1992)
[84]
Primary congenital bladder diverticula in boys. — Stage KH, Tank ES Urology (1992)
[85]
Neurogenic tumor of the urinary bladder (a case report). — Sane SY, Garpure SS, Borwankar SS Journal of postgraduate medicine (1991)
[86]
Schistosomiasis and sarcoma of the urinary bladder. — Alwan MH, Sayed M, Kamal MM European urology (1988)
[87]
Bladder diverticula in elderly females with urgency, dysuria and incontinence. — Gillon G, Nissenkorn I, Servadio C European urology (1988)
[88]
Malacoplakia presenting as a pseudotumor of the bladder in cadaveric renal transplantation. — Baniel J, Shmueli D, Shapira Z, Sandbank Y, Servadio C The Journal of urology (1987)
[89]
Endoscopic bladder transection for detrusor instability. — Lucas MG, Thomas DG British journal of urology (1987)
[90]
Intraoperative consultation for the bladder. — Spirnak JP, Resnick MI The Urologic clinics of North America (1985)
[91]
Comparison between cell kinetical and immunohistochemical studies on carcinoma and atypia/dysplasia of urinary bladder mucosa. — Helpap B, Vogel J, Oehr P, Adolphs HD Virchows Archiv. A, Pathological anatomy and histopathology (1985)
[92]
Origin and distribution of neuropeptide Y-, vasoactive intestinal polypeptide-and substance P-containing nerve fibers in the urinary bladder of the rat. — Mattiasson A, Ekblad E, Sundler F, Uvelius B Cell and tissue research (1985)
[93]
Pre-existing uninhibited bladder facilitating drug-induced enuresis: four case reports. — Schwarcz G Canadian journal of psychiatry. Revue canadienne de psychiatrie (1983)
[94]
The clinical value of bladder capacity measurement at physiological pressure under anaesthesia. — Powell PH, Yeates WK British journal of urology (1982)
[95]
A case of urethral malacoplakia associated with vesical disease. — McClure J The Journal of urology (1979)
[96]
Diverticula of the bladder in children. — Boechat MI, Lebowitz RL Pediatric radiology (1978)
[97]
Transvesical submucosal diverticulectomy. Experience with 48 cases. — Firstater M, Farkas A Urology (1977)
[98]
An improved surgical technique for intra-vesical resection of bladder diverticula. — Colodny AH British journal of urology (1975)
[99]
Prolonged bladder distension in the treatment of the unstable bladder. — Whitfield HN, Mayo ME British journal of urology (1975)

Share:Twitter Reddit LinkedIn